Ixazomib Shows Promise as Option for Chronic GVHD Ixazomib Shows Promise as Option for Chronic GVHD

Patients with advanced chronic graft versus host disease who have failed multiple therapies may respond to ixazomib, a drug approved for second-line multiple myeloma treatment, say US scientists.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news